KOLOREKTAL SARATON BILAN OG'RIGAN BEMORLARDA MAQSADLI DAVOLASH TAKTIKASINI INDIVIDUALLASHTIRISH IMKONIYATLARINI O'RGANISH METASTATIK JIGAR SHIKASTLANISHI BILAN
Keywords:
Kalit so'zlar: bevasizumab, individual omillar, kolorektal saraton, jigar metastazlari, kimyoterapiya, tsetuksimabAbstract
Hozirgi vaqtda jigar metastazlari bo'lgan kolorektal saraton (KRS) bilan og'rigan bemorlarda davolash taktikasi va maqsadli terapiyadan foydalanish bo'yicha turli xil fikrlar mavjud. Tadqiqotga KRS va metastatik jigar kasalligi bo'lgan 75 bemor kiritildi. Barcha bemorlar bevacizumab va cetuximab maqsadli dorilar bilan birgalikda XELOX / FOLFOX4 rejimlariga muvofiq operatsiyadan oldin kimyoterapiya (KT) oldilar. Eng yaxshi davolash natijalari bevacizumab bilan kimyoterapiya kombinatsiyasi bilan ko'rsatildi. Jigar metastazlari bo'lgan KRS bilan og'rigan bemorlarni uzoq muddatli davolash natijalariga ta'sir ko'rsatadigan individual klinik va laboratoriya xavf omillari aniqlandi, bu esa ushbu toifadagi bemorlarda maqsadli davolash taktikasini individuallashtirishga yordam berishi mumkin.
References
1. Amosenko F.A., Karpov I.V., Polyakov A.V. va boshq. Kolorektal saratonda CRAS genidagi somatik mutatsiyalarning molekulyar-genetik tahlilining turli usullarini taqqoslash. 2012. No2. Pp. 35–41.
2. Izrailbekova K., Kamysov S.V., Cabanillas M. Onkologik kasalliklarda maqsadli davolash qarshiligini oldini olish va bartaraf etish bo'yicha strategik kombinatsiyalar. Nazariy va klinik tibbiyot jurnali. 2020 y. No 3. Pp. 184-197.
3. Kamyshov S.V., Pulatov D.A., Yuldasheva N.Sh. Bachadon bo'yni saratoni bo'lgan bemorlarda kimyoradioterapiyaning toksik ta'sirini kamaytirishda ekstrakorporeal immunofarmakoterapiyaning rolini o'rganish. Evroosiyo onkologiya jurnali. 2015. T.7. No4. P.28-34.
4. Kamyshov S.V. Bachadon bo'yni saratonini kompleks davolashda zamonaviy immunfarmakkoterapiya. Fan va ta'lim byulleteni. 2018. No6 (42). Vol.2. P.57-61. DOI: 10.20861/2304-2338-2018-127-007
5. Prorokov V.V., Vlasov O.A., Tupitsin N.N. Kolorektal saraton kasalligi davolash muammosi va prognozining hozirgi holati. 2014. T.60. No2 (114). P.28-33.
1. Arnold M., Sierra M.S., Laversanne M. et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-691.
2. Bassim J.A., Itrat M. Expanding Role of Bio Markers in Colo-Rectal Cancer (KRS). Int. J. Cell. Sci & Mol. biol. 2017;3(1):555-605.
3. Bittoni A., Sotte V., Meletani T. et al. Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives. J Cancer Metastasis Treat. 2018;4(55). doi: 10.20517/2394-4722.2018.37.
4. Goswami R.S., Patel K.P., Singh R.R. et al. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015;21(11):2644-2651. doi: 10.1158/1078-0432.CCR-14-2391
5. Jauhri M., Bhatnagar A., Gupta S., et al. Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing. Med Oncol. 2016;33(10):106. doi: 10.1007/s12032-016-0820-2 PMID: 27568332
6. Modest D.P., Martens U.M., Riera-Knorrenschild J., et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019;37(35):3401-3411. doi: 10.1200/JCO.19.01340.
7. Paul R., David R.F., Radek L. et al. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer. 2015;51:18-26.
